Complete Response to FOLFOX4 Therapy in a Patient with Advanced Urothelial Cancer

Strategic Insights -

A new case report published in the Journal of Hematology & Oncology has highlighted the potential of FOLFOX4 therapy as a salvage treatment for patients with advanced urothelial cancer who are refractory to gemcitabine. The study, conducted by researchers from Soonchunhyang University, reported a complete response to FOLFOX4 therapy in a 54-year-old patient with metastatic urothelial cancer. The patient had previously undergone adjuvant gemcitabine plus cisplatin combination chemotherapy, but had developed new metastases and synchronous primary colon cancer. After receiving FOLFOX4 chemotherapy, the patient's liver and lung metastasis lesions disappeared, along with the primary colon cancer. The patient remained in complete response for 4 months after the last cycle of therapy.

Key Takeaways:

  • A 54-year-old male patient with advanced urothelial cancer achieved a complete response to FOLFOX4 therapy after failing gemcitabine-based treatment.
  • The patient had undergone extensive radical nephrectomy and received three rounds of adjuvant gemcitabine-cisplatin chemotherapy.
  • The patient's lung metastasis lesion was confirmed via percutaneous transthoracic needle biopsy (PTNB) to be a metastatic urothelial cancer.
  • Liver and lung metastasis lesions disappeared after the 4th cycle of FOLFOX4 chemotherapy, along with the primary colon cancer.
  • The patient remained in complete response for 4 months after the last cycle of FOLFOX4 therapy.
  • The researchers concluded that clinical trials using the FOLFOX regimen as salvage therapy for gemcitabine-refractory advanced urothelial cancer are warranted.

Statistics:

  • Age of patient: 54 years
  • Number of cycles of FOLFOX4 chemotherapy taken: 8
  • Time to complete response: 4 months after last cycle of therapy
  • Number of metastasis lesions: 3 (liver, lung, and primary colon cancer)
  • Percentage of response: 100% (complete response)
  • Average response time: 4 months

Sources:

  • Seo, Y.R., et al. (2010). Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report. Journal of Hematology & Oncology, 2010;3():4.
  • Blood Weekly (2010). Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report. Blood Weekly via NewsRx.com.